Andere Sprachen Bristol-Myers Squibb Company Wiener Boerse

Aktien

BMYS

US1101221083

BMYS

Realtime-Estimate Tradegate Andere Börsenplätze 15:00:11 18.06.2024			% 5 Tage	% 1. Jan.
38,26 ^EUR	+0,18 %		-1,52 %	-17,59 %

12:59	Bristol Myers Squibb beschließt eine vierteljährliche Dividende, zahlbar am 1. August 2024	CI
13.06.	Augtyro von Bristol-Myers Squibb erhält beschleunigte FDA-Zulassung zur Behandlung von soliden Tumoren	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Bristol Myers : dividendes décidés par le conseil	13:26
Bristol Myers Squibb Announces Dividend	13:00
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	12:59
Bristol Myers : approbation de la FDA pour un traitement	14.06.
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	13.06.
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	13.06.
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13.06.
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13.06.
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12.06.
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12.06.
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12.06.
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10.06.
Geron shares surge after U.S. FDA approves blood disorder drug	07.06.
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05.06.
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma	05.06.
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05.06.
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	04.06.
Bristol Myers : résultats positifs dans le cancer du foie	04.06.
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial	04.06.
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial	04.06.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Bristol-Myers CEO sagt, das Unternehmen sei im Umbruch

Am 09. Januar 2024 um 19:06 Uhr